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Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic
T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with
metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer
immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first
case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic
liver transplantation with a partial response. Transaminitis was observed 4 months after administration of ipilimumab
that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for
further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients.Background
Patients presenting with melanoma after solid organ
transplantation present unique challenges to oncologists.
There are several important considerations in this set-
ting, including the risk of injury to the allograft with
the administration of anticancer therapy and the scar-
city of published data regarding the clinical manage-
ment of advanced melanoma in organ transplant
recipients. This is especially relevant given the recent
development of immunomodulatory therapies for the
treatment of metastatic melanoma. Ipilimumab is a
first-in-class immunological checkpoint blockade agent
approved by the United States Food and Drug Adminis-
tration (FDA) in 2011 for the treatment of unresectable
or metastatic melanoma. Two phase III studies have
demonstrated improved overall survival rates with
ipilimumab as compared to dacarbazine or a peptide
vaccine control [1,2], Long-term disease control has
been documented in approximately 20% of individuals
treated [3]. Given the success of ipilimumab in ad-
vanced melanoma, it is important to consider the safety
and efficacy of this agent in solid organ transplant* Correspondence: carvajalr@columbia.edu
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unless otherwise stated.recipients. The only published experience administer-
ing drug to a solid organ transplant recipient is by Lipson
and colleagues [4], who reported two cases of successful
administration of ipilimumab to patients with kidney
transplants. Here, we present the first case describing the
use of ipilimumab in a patient with a liver transplant.Case presentation
A 67-year-old man with a history of hepatitis C virus
(HCV) and hepatocellular carcinoma (HCC) underwent
orthotopic liver transplantation in 2006. He presented
with decompensated liver disease marked by ascites and
hepato-renal syndrome leading to renal failure. He was
on hemodialysis prior to transplant and had a Model for
End-Stage Liver Disease (MELD) score of 35 at time of
transplant. His donor was a 49-year-old man with no
history of malignancy. Explant pathology revealed estab-
lished cirrhosis with a 2.5 cm moderately differentiated
HCC with evidence of microvascular invasion. After
transplantation, he maintained stable liver function on
an immunosuppressive regimen of tacrolimus and myco-
phenolate mofetil. He underwent two post-transplant
liver biopsies, which revealed HCV recurrence: Grade 1,
Stage 1 in 2008 and Grade 1, Stage 2 in 2010. His liverl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Morales et al. Journal for ImmunoTherapy of Cancer  (2015) 3:22 Page 2 of 4enzymes remained in the normal range at this time. He
underwent HCC surveillance at 6 monthly intervals for
the first 2 years after transplant and yearly thereafter for
the next 3 years.
In 2007, a small pigmented skin lesion above his left
eyebrow grew larger and became ulcerated. A biopsy in
September 2009 revealed an ulcerated melanoma at least
0.7 mm in Breslow thickness. Wide local excision with
sentinel lymph node biopsy performed in November 2009
demonstrated residual ulcerated melanoma, 2.51 mm
thick, Clark Level IV, with a mitotic index of 11/mm2 and
no lymphovascular or perineural invasion. Two sentinel
nodes were negative for disease. Initial clinical staging by
American Joint Committee on Cancer (AJCC) 7th edition
was T3bN0, Stage IIB. In 2010, HCC surveillance imaging
revealed a 5 cm right adrenal mass that was subsequently
resected. The pathology revealed metastatic HCC. At this
point his immunosuppression was switched from tacroli-
mus to rapamycin 3 mg daily and he was continued on
mycophenolate mofetil 500 mg twice daily.
The patient underwent active surveillance with clinical
exams and imaging studies until October 2013, when he
noticed a swollen mass in the left parotid region. A nee-
dle biopsy revealed melanoma wild-type for BRAF and
cKIT. A positron emission tomography/computerized
tomography (PET/CT) scan performed in November
2013 demonstrated prominent focal hypermetabolic
activity in bilateral lung nodules, bony foci and a parotid
lesion, consistent with M1c disease. Magnetic resonance
imaging (MRI) of the brain showed no evidence of
metastases. A repeat scan in January 2014 showed in-
creasing nodal and bony disease and new hepatic metas-
tases in the allograft. At that point, he was initiated on
therapy with paclitaxel. His rapamycin was reduced from
3 mg to 1 mg daily and mycophenolate mofetil was dis-
continued, given prior clinical reports documenting
tumor regression with reduction of immunosuppression
[5,6]. He completed 5 cycles of chemotherapy as well as
14 of 20 planned fractions of palliative radiotherapy to
the hip before experiencing multifocal disease progres-
sion in April 2014, with increasing disease burden in the
lungs, mediastinal lymph nodes, liver and spleen.
After a multidisciplinary team-based discussion in-
cluding both medical oncology and transplant medicine,
the decision was made to begin therapy on ipilimumab
while maintaining rapamycin at 1 mg daily. Given the
increased risk of graft rejection, the treatment plan
included weekly monitoring of liver function tests. The
patient received his four induction doses of ipilimumab
3 mg/kg between April 2014 and July 2014. The patient
experienced a mild non-pruritic rash on his torso after
the second infusion, which lasted one week and re-
solved with topical steroids. The aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) and alkalinephosphatase were mildly elevated at baseline (Common
Terminology Criteria for Adverse Events [CTCAE] v4.0
Grade 1) and remained stable throughout the course of
treatment. Total bilirubin was within normal limits at
baseline and remained normal throughout the course of
treatment. The fourth and final dose of ipilimumab was
administered at week 10, on 7/1/2014. On week 12, a
Grade 2 transaminitis and alkaline phosphatase eleva-
tion developed, with no associated hyperbilirubinemia.
The patient was managed conservatively with frequent
laboratory tests. AST and ALT levels peaked at a Grade
3 on week 16 with stabilization or improvement the
following week without intervention (Figure 1). Because
the patient remained asymptomatic and compliant with
weekly laboratory testing, it was decided to maintain
him on close monitoring and defer initiation of cortico-
steroids. Alkaline phosphatase levels peaked at week 17,
but remained Grade 1 throughout the course of treat-
ment. At last monitoring in February 2015, this value
had returned to within normal limits. Total bilirubin
has remained within normal limits since the induction
of treatment. By week 20, all lab values resolved to
Grade 1, and conservative management was continued.
The patient declined a recommended liver biopsy. The
patient remains stable 10 months following induction of
treatment.
Repeat CT scans conducted in July 2014, after his
fourth infusion of ipilimumab, showed dramatic tumor
regression in the lungs (Figure 2a) as well as the liver
(Figure 2b). Clinically, the patient continues to feel well
and is undergoing continued close monitoring for both
his liver function and disease status.
Conclusions
Compared to the general population, organ transplant
recipients (OTRs) have an estimated 2.4 fold increased
risk of developing melanoma [7]. Prognosis for these
patients is also estimated to be worse than those with
non-transplant associated melanomas. Brewer and col-
leagues [8] performed the largest retrospective review of
patients with melanoma arising post-transplant to date,
which demonstrated decreased overall survival for OTRs
with localized melanomas with Breslow thickness >1.5 mm
or Clark Levels III and IV, compared to immunocompetent
controls. They also found that the degree of immunosup-
pression was negatively correlated with survival.
Given the increased risk for melanoma in solid organ
transplant patients as well as poor outcomes, the devel-
opment of treatment strategies for this population is
necessary. Two previously published case reports have
described complete responses of metastatic melanoma
after withdrawal of immunosuppressive medications in
aplastic anemia and myasthenia gravis, without signifi-























Figure 1 Demonstration of changes in AST/ALT values over time with administration of ipilimumab; AST and ALT levels were measured weekly
during the administration of ipilimumab. Sixteen weeks following initial induction, AST and ALT levels peaked at Grade 3. Resolution to Grade 1
was seen at Week 20, and monthly monitoring of liver function tests has been performed since, with continued evidence of stability. Arrows
denote the times of administration of ipilimumab.
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be feasible in the setting of solid organ transplantation.
Therefore, therapeutic options for the advanced melanoma
must include consideration of agents such as ipilimumab.
There are at least two barriers to the use of immune
checkpoint inhibitors such as ipilimumab in OTRs. Firstly,
because ipilimumab ostensibly requires a competent T-Baseline
a)
b)
Figure 2 Demonstration of radiographic response to ipilimumab; CT scans
demonstrate regression of lung and liver metastases (arrows).cell population to carry out its antitumor function, the co-
administration of immunosuppressive agents such as rapa-
mycin to prevent graft rejection may impact the efficacy of
ipilimumab in this population. In this case, the patient was
maintained on low-dose immunosuppression with rapa-
mycin throughout his course of treatment with ipilimu-
mab. However, given his marked radiographic responseWeek 12
performed prior to and 12 weeks after initiation of therapy
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mab was not significantly affected by his concurrent
immunosuppression.
A second barrier to treatment in cases such as this
stems from the ability of drugs such as ipilimumab to
activate T cells that may be specific for non-self antigens
expressed by the allograft, precipitating organ rejection.
In our patient, there was initial concern for an adverse
immune reaction to treatment, especially given the rise
in liver function tests that was seen after 12 weeks of
treatment. However, with no further ipilimumab admin-
istration and expectant observation, the patient’s transa-
minitis resolved to near baseline levels within 8 weeks.
Given these challenges, it is important to identify which
patients may tolerate a reduction of immunosuppression
as well as the use of immunomodulatory agents. Although
no definitive prognostic markers have been identified, sev-
eral studies have identified increased length of time since
transplantation as a predictive factor for tolerance of
immunosuppression withdrawal [9,10]. In addition,
compared with other organs such as the heart and lung,
liver grafts are considered to be the least immunogenic
organs for transplant and thus can sustain less aggres-
sive immunosuppressive regimens [11]. The patient de-
scribed above received his liver transplant 8 years
before induction with ipilimumab, and was thus able to
tolerate reductions to his immunosuppressive regimen
before induction with ipilimumab. This, along with
close monitoring of liver function and immunosuppres-
sive drug levels, may have contributed to our success in
treating him both safely and effectively with this drug.
Although further study in a large patient cohort is
warranted, this case has demonstrated the feasibility and
efficacy in administering ipilimumab to a liver transplant
recipient, and may suggest that liver transplant recipients
several years post-transplant may be appropriate candi-
dates for trials with immunomodulatory treatments. Our
small sample size underscores the importance of reporting
safety and efficacy data for ipilimumab in the solid tumor
organ transplant population. Furthermore, the promising
data from trials of programmed cell death-1 (PD-1) and
programmed death-ligand 1 (PD-L1) antibodies in meta-
static melanoma make it especially important to study the
potential effects of immune checkpoint inhibitors in im-
munocompromised patients. The risks surrounding graft
rejection in the setting of immune activation with these
agents must be strongly considered when making treat-
ment decisions in this population.
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